Qilu Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has officially accepted the marketing application for Meropenem/Pralurbactam for Injection, an independently developed Category 1 chemical drug. The product is positioned as the first independently developed novel β‑lactamase inhibitor combination in China intended for the treatment of complicated intra‑abdominal infections (cIAI) — and, critically, as a potential answer to carbapenem‑resistant Enterobacterales (CRE), including metallo‑β‑lactamase–producing strains that defeat most existing therapies.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Filing Type | Marketing application – officially accepted |
| Product | Meropenem/Pralurbactam for Injection |
| Classification | Category 1 chemical drug (independently developed) |
| Indication | Complicated intra‑abdominal infections (cIAI) |
| Acceptance Date | 17 Sep 2026 |
| Next Steps | NMPA/CDE technical review – timeline not disclosed |
Drug Profile & Mechanism of Action
- Composition: Fixed combination of meropenem, a widely used carbapenem antibiotic, with pralurbactam, the program’s core novel component.
- Inhibitor Class: Pralurbactam is a novel DBO‑structured (diazabicyclooctane) β‑lactamase inhibitor, engineered to restore meropenem activity against resistant pathogens.
- Innovation: First independently developed novel β‑lactamase inhibitor combination in China targeting cIAI.
- Resistance Rationale: CRE — Enterobacterales resistant to carbapenems such as meropenem and imipenem — are important pathogens in hospital‑acquired infections, leaving clinicians with few reliable options.
- Development Status: Marketing application accepted; clinical trial datasets and review timelines not disclosed.
In Vitro Evidence – Carbapenemase Coverage
| Carbapenemase Class | Enzyme | Coverage (In Vitro) |
|---|---|---|
| Class A | KPC | Covered |
| Class B (metallo‑β‑lactamase) | NDM | Covered – excellent activity vs. NDM‑type resistant E. coli |
| Class D | OXA‑48 | Covered |
In vitro studies show that Meropenem/Pralurbactam can cover CRE strains producing Class A (KPC), Class B (NDM), and Class D (OXA‑48) carbapenemases, with particularly strong antibacterial activity against NDM‑type drug‑resistant Escherichia coli. The breadth across all three classes — notably the metallo‑β‑lactamase (MBL) enzymes — is expected to address the shortcomings of existing therapeutic drugs, most of which fail against MBL‑producing strains. Clinical efficacy and safety data in patients were not disclosed in the announcement.
Market Impact & Outlook
- Unmet Need in MBL Coverage: Several marketed β‑lactam/β‑lactamase inhibitor combinations retain activity against KPC‑producing CRE but are inactive against metallo‑β‑lactamases such as NDM, often forcing clinicians into aztreonam‑based salvage regimens. A single agent spanning Class A, B, and D enzymes would fill a recognized gap in the antibacterial armamentarium.
- China nosocomial landscape: NDM‑type carbapenemase producers are a prominent resistance mechanism among hospital‑acquired Enterobacterales in China, elevating the strategic value of an indigenously developed combination with MBL coverage.
- Qilu Pipeline Signal: The acceptance underscores Qilu Pharmaceutical’s push into high‑value innovative anti‑infectives beyond its generics base; commercial plans and pricing were not disclosed.
- Next Catalysts: Outcome and timing of the NMPA technical review; any subsequent clinical data disclosures or priority‑review designation — all not yet disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review, clinical performance, and commercial potential of Meropenem/Pralurbactam for Injection. Acceptance of a marketing application does not guarantee approval. Actual results may differ materially due to risks including review outcomes, safety and efficacy findings, reimbursement dynamics, and evolving resistance patterns. In vitro activity may not translate into clinical benefit.-Fineline Info & Tech
